



**New Lower Prices for First Ten Drugs Selected for Medicare Price Negotiation to Lower Costs for New Mexicans**

The [Biden-Harris administration](#) announced the first 10 drugs selected for Medicare price negotiation, which was made [possible through provisions Heinrich passed in the Inflation Reduction Act](#).

The new prices will go into effect for people with Medicare Part D prescription drug coverage in 2026:

Drug Name	Commonly Treated Conditions	Number of Medicare Enrollees Who Used the Drug in 2023	Drug List Price in 2023 for 30-day Supply	Negotiated Price for 2026 for 30-day Supply	Savings (%)
Eliquis	Prevention and treatment of blood clots	3,928,000	\$521	\$231	\$290 (-56%)
Jardiance	Diabetes; Heart failure; Chronic kidney disease	1,883,000	\$573	\$197	\$376 (-66%)
Xarelto	Prevention and treatment of blood clots; Reduction of risk for patients with coronary or peripheral artery disease	1,324,000	\$517	\$197	\$320 (-62%)
Januvia	Diabetes	843,000	\$527	\$113	\$414 (-79%)
Farxiga	Diabetes; Heart failure; Chronic kidney disease	994,000	\$556	\$178.50	\$377.50 (-68%)
Entresto	Heart failure	664,000	\$628	\$295	\$333 (-53%)
Enbrel	Rheumatoid arthritis; Psoriasis; Psoriatic arthritis	48,000	\$7,106	\$2,355	\$4,751 (-67%)

Imbruvica	Blood cancers	17,000	\$14,934	\$9,319	\$5,615 (-38%)
Stelara	Psoriasis; Psoriatic arthritis; Crohn's disease; Ulcerative colitis	23,000	\$13,836	\$4,695	\$9,141 (-66%)
Fiasp; Fiasp FlexTouch; Fiasp PenFill; NovoLog; NovoLog FlexPen; NovoLog PenFill	Diabetes	785,000	\$495	\$119	\$376 (-76%)

More drugs will be selected each year as part of Medicare's drug price negotiation program. Medicare will select up to 15 additional drugs covered under Part D for negotiation in 2025, up to an additional 15 Part B and D drugs in 2026, and up to 20 drugs every year after that.

###